The biotechnology industry has been experiencing significant growth, driven by emerging trends such as advancements in genomic research, personalized medicine, and innovative biotechnology platforms. These advancements have enabled more precise and targeted treatments, particularly in areas like oncology, rare diseases, and immunotherapies.
Among the key stocks leading the charge in this space are Harmony Biosciences Holdings, Inc. (HRMY), Treda Pharmaceuticals, Inc. (TRDA), and Puma Biotechnology, Inc. (PBYI), each focused on developing breakthrough therapies. So, they could be ideal buys now.
